Subscribe to our newsletter.
Copyright 2025 © All rights Reserved Goffin Molecular Technologies
X
- No products in the list
The TRUPCR® Acute Leukemia Panel Kit is an in vitro Real-Time PCR assay developed for the qualitative detection of key diagnostic and prognostic gene alterations associated with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). Designed for use with peripheral blood samples, the assay enables detection of a wide spectrum of genetic mutations and fusion transcripts commonly involved in leukemogenesis, aiding in the stratification, diagnosis, and therapeutic decision-making.
By targeting clinically significant markers including FLT3-ITD, NPM1, JAK2 V617F, CBFB-MYH11, PML-RARA, AML1-ETO, and BCR-ABL (p210, p190, p230), the kit provides a consolidated, high-throughput solution for hematologic labs. It supports rapid and specific identification of Class I and Class II mutations that govern leukemic transformation, proliferation, and prognosis.
The test includes all reagents for cDNA synthesis and amplification and is compatible with major qPCR platforms, delivering reliable results in under 2 hours. Ideal for routine clinical use, the TRUPCR® Acute Leukemia Panel streamlines molecular testing in leukemia workflows.
The TRUPCR® Acute Leukemia Panel Kit is a multiplex real-time PCR-based in vitro diagnostic assay designed for the qualitative detection of genetic markers associated with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). This comprehensive panel enables simultaneous detection of fusion transcripts and point mutations that are clinically relevant for the diagnosis, prognosis, and therapeutic stratification of leukemia patients.
The assay covers a wide range of genomic targets including fusion genes such as PML-RARA, BCR-ABL, AML1-ETO, and CBFB-MYH11, as well as somatic mutations in FLT3, NPM1, and JAK2. Each target is amplified using optimized primer-probe chemistry to ensure high specificity and sensitivity. Internal control genes (e.g., ABL1) are included to assess sample quality and enable reliable result interpretation.
This consolidated workflow reduces the need for multiple assays, supporting high-throughput leukemia diagnostics with minimal hands-on time.
Acute leukemias are characterized by the clonal expansion of immature blood cell precursors, leading to suppression of normal hematopoiesis. AML and ALL are the two major subtypes, each with distinct genetic profiles. Accurate identification of class I mutations (e.g., FLT3, JAK2 – related to proliferation and survival) and class II mutations/fusions (e.g., NPM1, PML-RARA, AML1-ETO – affecting differentiation) is critical for patient management and risk stratification.
The TRUPCR® Acute Leukemia Panel enables broad molecular profiling across both subtypes:
These targets offer diagnostic, prognostic, and therapeutic relevance, making this panel highly valuable in both routine and advanced clinical settings.
The TRUPCR® Acute Leukemia Panel Kit provides accurate, reproducible detection of leukemia-related mutations and fusions in a single workflow. Its design supports:
Optimized for performance on widely used qPCR platforms, the assay ensures robust results even with low-input DNA/RNA samples.
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.
Subscribe to our newsletter.